The Cancer Supportive Care Market by Therapeutic Area, Distribution Channel, and Geography – Forecast and Analysis 2023-2027 report has been published by Technavio. Market size is forecast to grow by USD 6563.92 million between 2022 and 2027 at a CAGR of 4.62%. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. The report includes historic market data from 2017 to 2021. In 2017, the cancer supportive care market was valued at USD 23,156.29 million. Download A PDF Sample Report
Regional analysis
By region, the global laboratory shaker market is segmented into North America, Europe, Asia, and Rest of World (ROW). North America will account for 39% of market growth during the forecast period. Factors such as the huge investments in the pharmaceutical industry, specifically the oncology sector, and the presence of pharmaceutical giants in the region are driving the growth of the laboratory shaker market in North America. Buy the report
Company profiles
The cancer supportive care market report includes information on the key products and recent developments of leading vendors, including:
Amgen Inc. – The company offers cancer-supportive care products such as Neulasta and Aranesp.
Baxter International Inc. – The company offers cancer-supportive care facilities such as oncology to prevent nutritional deficits.
Bayer AG – The company offers cancer-supportive care facilities for India and Egypt.
Market dynamics
The market is driven by factors such as the growing prevalence of cancer cases, the many side effects associated with cancer treatment, and the untapped potential in developing countries. However, the high cost of cancer treatment is hindering the market growth.
Competitive analysis
The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share among others. Request a Sample
Market segmentation
- By therapeutic area, the market is segmented into chemotherapy-induced anemia, chemotherapy-induced neutropenia, cancer pain, CINV, and others. The chemotherapy-induced anemia segment accounted for the largest share of the market in 2022.
- By geography, the market is segmented as North America, Europe, Asia, and Rest of World (ROW). North Americaheld the largest share of the market in 2022.
Related Reports:
The burn care market is estimated to grow at a CAGR of 5.27% between 2022 and 2027. The size of the market is forecast to increase by USD 843.34 million. This report extensively covers market segmentation by therapy (advanced burn care, biologics, and traditional burn care), type (third-degree (full thickness) burns, second-degree (partial thickness) burns, and first-degree (superficial) burns), and geography (North America, Europe, Asia, and Rest Of World (ROW)).
The lung cancer therapeutics market is estimated to grow at a CAGR of 7.92% between 2022 and 2027. The size of the market is forecast to increase by USD 10,204.33 million. This report extensively covers market segmentation by therapy (targeted therapy, immunotherapy, and chemotherapy), type (NSCLC and SCLC), and geography (North America, Europe, Asia, and Rest of World (ROW)).
Technavio’s library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our “Basic Plan” at just USD 5,000 and get lifetime access to Technavio Insights
What are the key data covered in this cancer supportive care market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the cancer supportive care market between 2023 and 2027
- Precise estimation of the cancer supportive care market size and its contribution to the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of cancer-supportive care market vendors
| Cancer Supportive Care Market Scope | |
| Report Coverage | Details |
| Page number | 175 |
| Base year | 2022 |
| Historic period | 2017-2021 |
| Forecast period | 2023-2027 |
| Growth momentum & CAGR | Accelerate at a CAGR of 4.62% |
| Market growth 2023-2027 | USD 6,563.92 million |
| Market structure | Fragmented |
| YoY growth 2022-2023 (%) | 3.92 |
| Regional analysis | North America, Europe, Asia, and Rest of World (ROW) |
| Performing market contribution | North America at 39% |
| Key countries | US, Canada, UK, Germany, and China |
| Competitive landscape | Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
| Key companies profiled | Acacia Pharma Group Plc, Amgen Inc., Baxter International Inc., Bayer AG, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Helsinn Healthcare SA, Heron Therapeutics Inc., Johnson and Johnson, Kyowa Kirin Co. Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Purdue Pharma LP, RELIEF THERAPEUTICS Holding SA, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. |
| Market dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
1 Executive Summary
- 1.1 Market Overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapeutic Area
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global cancer supportive care market 2017 – 2021
- Exhibit 18: Historic Market Size – Data Table on Global cancer supportive care market 2017 – 2021 ($ million)
- 4.2 Therapeutic area Segment Analysis 2017 – 2021
- Exhibit 19: Historic Market Size – Therapeutic area Segment 2017 – 2021 ($ million)
- 4.3 Distribution channel Segment Analysis 2017 – 2021
- Exhibit 20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 – 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
- 4.5 Country Segment Analysis 2017 – 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
6 Market Segmentation by Therapeutic Area
- 6.1 Market segments
- Exhibit 30: Chart on Therapeutic Area – Market share 2022-2027 (%)
- Exhibit 31: Data Table on Therapeutic Area – Market share 2022-2027 (%)
- 6.2 Comparison by Therapeutic Area
- Exhibit 32: Chart on Comparison by Therapeutic Area
- Exhibit 33: Data Table on Comparison by Therapeutic Area
- 6.3 Chemotherapy-induced anemia – Market size and forecast 2022-2027
- Exhibit 34: Chart on Chemotherapy-induced anemia – Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Chemotherapy-induced anemia – Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Chemotherapy-induced anemia – Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Chemotherapy-induced anemia – Year-over-year growth 2022-2027 (%)
- 6.4 Chemotherapy-induced neutropenia – Market size and forecast 2022-2027
- Exhibit 38: Chart on Chemotherapy-induced neutropenia – Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Chemotherapy-induced neutropenia – Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Chemotherapy-induced neutropenia – Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Chemotherapy-induced neutropenia – Year-over-year growth 2022-2027 (%)
- 6.5 Cancer pain – Market size and forecast 2022-2027
- Exhibit 42: Chart on Cancer pain – Market size and forecast 2022-2027 ($ million)
- Exhibit 43: Data Table on Cancer pain – Market size and forecast 2022-2027 ($ million)
- Exhibit 44: Chart on Cancer pain – Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on Cancer pain – Year-over-year growth 2022-2027 (%)
- 6.6 CINV – Market size and forecast 2022-2027
- Exhibit 46: Chart on CINV – Market size and forecast 2022-2027 ($ million)
- Exhibit 47: Data Table on CINV – Market size and forecast 2022-2027 ($ million)
- Exhibit 48: Chart on CINV – Year-over-year growth 2022-2027 (%)
- Exhibit 49: Data Table on CINV – Year-over-year growth 2022-2027 (%)
- 6.7 Others – Market size and forecast 2022-2027
- Exhibit 50: Chart on Others – Market size and forecast 2022-2027 ($ million)
- Exhibit 51: Data Table on Others – Market size and forecast 2022-2027 ($ million)
- Exhibit 52: Chart on Others – Year-over-year growth 2022-2027 (%)
- Exhibit 53: Data Table on Others – Year-over-year growth 2022-2027 (%)
- 6.8 Market opportunity by Therapeutic Area
- Exhibit 54: Market opportunity by Therapeutic Area ($ million)
7 Market Segmentation by Distribution Channel
- 7.1 Market segments
- Exhibit 55: Chart on Distribution Channel – Market share 2022-2027 (%)
- Exhibit 56: Data Table on Distribution Channel – Market share 2022-2027 (%)
- 7.2 Comparison by Distribution Channel
- Exhibit 57: Chart on Comparison by Distribution Channel
- Exhibit 58: Data Table on Comparison by Distribution Channel
- 7.3 Hospitals pharmacies – Market size and forecast 2022-2027
- Exhibit 59: Chart on Hospitals pharmacies – Market size and forecast 2022-2027 ($ million)
- Exhibit 60: Data Table on Hospitals pharmacies – Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Chart on Hospitals pharmacies – Year-over-year growth 2022-2027 (%)
- Exhibit 62: Data Table on Hospitals pharmacies – Year-over-year growth 2022-2027 (%)
- 7.4 Drug stores and retail pharmacies – Market size and forecast 2022-2027
- Exhibit 63: Chart on Drug stores and retail pharmacies – Market size and forecast 2022-2027 ($ million)
- Exhibit 64: Data Table on Drug stores and retail pharmacies – Market size and forecast 2022-2027 ($ million)
- Exhibit 65: Chart on Drug stores and retail pharmacies – Year-over-year growth 2022-2027 (%)
- Exhibit 66: Data Table on Drug stores and retail pharmacies – Year-over-year growth 2022-2027 (%)
- 7.5 Online providers – Market size and forecast 2022-2027
- Exhibit 67: Chart on Online providers – Market size and forecast 2022-2027 ($ million)
- Exhibit 68: Data Table on Online providers – Market size and forecast 2022-2027 ($ million)
- Exhibit 69: Chart on Online providers – Year-over-year growth 2022-2027 (%)
- Exhibit 70: Data Table on Online providers – Year-over-year growth 2022-2027 (%)
- 7.6 Market opportunity by Distribution Channel
- Exhibit 71: Market opportunity by Distribution Channel ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 73: Chart on Market share by geography 2022-2027 (%)
- Exhibit 74: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 75: Chart on Geographic comparison
- Exhibit 76: Data Table on Geographic comparison
- 9.3 North America – Market size and forecast 2022-2027
- Exhibit 77: Chart on North America – Market size and forecast 2022-2027 ($ million)
- Exhibit 78: Data Table on North America – Market size and forecast 2022-2027 ($ million)
- Exhibit 79: Chart on North America – Year-over-year growth 2022-2027 (%)
- Exhibit 80: Data Table on North America – Year-over-year growth 2022-2027 (%)
- 9.4 Europe – Market size and forecast 2022-2027
- Exhibit 81: Chart on Europe – Market size and forecast 2022-2027 ($ million)
- Exhibit 82: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
- Exhibit 83: Chart on Europe – Year-over-year growth 2022-2027 (%)
- Exhibit 84: Data Table on Europe – Year-over-year growth 2022-2027 (%)
- 9.5 Asia – Market size and forecast 2022-2027
- Exhibit 85: Chart on Asia – Market size and forecast 2022-2027 ($ million)
- Exhibit 86: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
- Exhibit 87: Chart on Asia – Year-over-year growth 2022-2027 (%)
- Exhibit 88: Data Table on Asia – Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
- Exhibit 89: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
- Exhibit 90: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
- Exhibit 91: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
- Exhibit 92: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
- 9.7 US – Market size and forecast 2022-2027
- Exhibit 93: Chart on US – Market size and forecast 2022-2027 ($ million)
- Exhibit 94: Data Table on US – Market size and forecast 2022-2027 ($ million)
- Exhibit 95: Chart on US – Year-over-year growth 2022-2027 (%)
- Exhibit 96: Data Table on US – Year-over-year growth 2022-2027 (%)
- 9.8 UK – Market size and forecast 2022-2027
- Exhibit 97: Chart on UK – Market size and forecast 2022-2027 ($ million)
- Exhibit 98: Data Table on UK – Market size and forecast 2022-2027 ($ million)
- Exhibit 99: Chart on UK – Year-over-year growth 2022-2027 (%)
- Exhibit 100: Data Table on UK – Year-over-year growth 2022-2027 (%)
- 9.9 Germany – Market size and forecast 2022-2027
- Exhibit 101: Chart on Germany – Market size and forecast 2022-2027 ($ million)
- Exhibit 102: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
- Exhibit 103: Chart on Germany – Year-over-year growth 2022-2027 (%)
- Exhibit 104: Data Table on Germany – Year-over-year growth 2022-2027 (%)
- 9.10 China – Market size and forecast 2022-2027
- Exhibit 105: Chart on China – Market size and forecast 2022-2027 ($ million)
- Exhibit 106: Data Table on China – Market size and forecast 2022-2027 ($ million)
- Exhibit 107: Chart on China – Year-over-year growth 2022-2027 (%)
- Exhibit 108: Data Table on China – Year-over-year growth 2022-2027 (%)
- 9.11 Canada – Market size and forecast 2022-2027
- Exhibit 109: Chart on Canada – Market size and forecast 2022-2027 ($ million)
- Exhibit 110: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
- Exhibit 111: Chart on Canada – Year-over-year growth 2022-2027 (%)
- Exhibit 112: Data Table on Canada – Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 113: Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 114: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 115: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 116: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 117: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 118: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 119: Matrix on vendor position and classification
- 12.3 Amgen Inc.
- Exhibit 120: Amgen Inc. – Overview
- Exhibit 121: Amgen Inc. – Product / Service
- Exhibit 122: Amgen Inc. – Key offerings
- 12.4 Baxter International Inc.
- Exhibit 123: Baxter International Inc. – Overview
- Exhibit 124: Baxter International Inc. – Business segments
- Exhibit 125: Baxter International Inc. – Key news
- Exhibit 126: Baxter International Inc. – Key offerings
- Exhibit 127: Baxter International Inc. – Segment focus
- 12.5 Bayer AG
- Exhibit 128: Bayer AG – Overview
- Exhibit 129: Bayer AG – Business segments
- Exhibit 130: Bayer AG – Key news
- Exhibit 131: Bayer AG – Key offerings
- Exhibit 132: Bayer AG – Segment focus
- 12.6 Daiichi Sankyo Co. Ltd.
- Exhibit 133: Daiichi Sankyo Co. Ltd. – Overview
- Exhibit 134: Daiichi Sankyo Co. Ltd. – Business segments
- Exhibit 135: Daiichi Sankyo Co. Ltd. – Key news
- Exhibit 136: Daiichi Sankyo Co. Ltd. – Key offerings
- Exhibit 137: Daiichi Sankyo Co. Ltd. – Segment focus
- 12.7 F. Hoffmann La Roche Ltd.
- Exhibit 138: F. Hoffmann La Roche Ltd. – Overview
- Exhibit 139: F. Hoffmann La Roche Ltd. – Business segments
- Exhibit 140: F. Hoffmann La Roche Ltd. – Key news
- Exhibit 141: F. Hoffmann La Roche Ltd. – Key offerings
- Exhibit 142: F. Hoffmann La Roche Ltd. – Segment focus
- 12.8 GlaxoSmithKline Plc
- Exhibit 143: GlaxoSmithKline Plc – Overview
- Exhibit 144: GlaxoSmithKline Plc – Business segments
- Exhibit 145: GlaxoSmithKline Plc – Key offerings
- Exhibit 146: GlaxoSmithKline Plc – Segment focus
- 12.9 Heron Therapeutics Inc.
- Exhibit 147: Heron Therapeutics Inc. – Overview
- Exhibit 148: Heron Therapeutics Inc. – Product / Service
- Exhibit 149: Heron Therapeutics Inc. – Key news
- Exhibit 150: Heron Therapeutics Inc. – Key offerings
- 12.10 Johnson and Johnson
- Exhibit 151: Johnson and Johnson – Overview
- Exhibit 152: Johnson and Johnson – Business segments
- Exhibit 153: Johnson and Johnson – Key news
- Exhibit 154: Johnson and Johnson – Key offerings
- Exhibit 155: Johnson and Johnson – Segment focus
- 12.11 Kyowa Kirin Co. Ltd.
- Exhibit 156: Kyowa Kirin Co. Ltd. – Overview
- Exhibit 157: Kyowa Kirin Co. Ltd. – Product / Service
- Exhibit 158: Kyowa Kirin Co. Ltd. – Key offerings
- 12.12 Merck and Co. Inc.
- Exhibit 159: Merck and Co. Inc. – Overview
- Exhibit 160: Merck and Co. Inc. – Business segments
- Exhibit 161: Merck and Co. Inc. – Key news
- Exhibit 162: Merck and Co. Inc. – Key offerings
- Exhibit 163: Merck and Co. Inc. – Segment focus
- 12.13 Novartis AG
- Exhibit 164: Novartis AG – Overview
- Exhibit 165: Novartis AG – Business segments
- Exhibit 166: Novartis AG – Key offerings
- Exhibit 167: Novartis AG – Segment focus
- 12.14 Purdue Pharma LP
- Exhibit 168: Purdue Pharma LP – Overview
- Exhibit 169: Purdue Pharma LP – Product / Service
- Exhibit 170: Purdue Pharma LP – Key offerings
- 12.15 Sanofi SA
- Exhibit 171: Sanofi SA – Overview
- Exhibit 172: Sanofi SA – Business segments
- Exhibit 173: Sanofi SA – Key news
- Exhibit 174: Sanofi SA – Key offerings
- Exhibit 175: Sanofi SA – Segment focus
- 12.16 Sun Pharmaceutical Industries Ltd.
- Exhibit 176: Sun Pharmaceutical Industries Ltd. – Overview
- Exhibit 177: Sun Pharmaceutical Industries Ltd. – Product / Service
- Exhibit 178: Sun Pharmaceutical Industries Ltd. – Key offerings
- 12.17 Teva Pharmaceutical Industries Ltd.
- Exhibit 179: Teva Pharmaceutical Industries Ltd. – Overview
- Exhibit 180: Teva Pharmaceutical Industries Ltd. – Business segments
- Exhibit 181: Teva Pharmaceutical Industries Ltd. – Key news
- Exhibit 182: Teva Pharmaceutical Industries Ltd. – Key offerings
- Exhibit 183: Teva Pharmaceutical Industries Ltd. – Segment focus
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 184: Inclusions checklist
- Exhibit 185: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 186: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 187: Research methodology
- Exhibit 188: Validation techniques employed for market sizing
- Exhibit 189: Information sources
- 13.5 List of abbreviations
- Exhibit 190: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio